Absorption, Distribution and Excretion
Topical corticosteroids can be absorbed from normal, intact skin. Skin inflammation and/or other disease processes may increase transdermal absorption.

Effects During Pregnancy and Lactation
◉ Overview of Medication Use During Lactation
Desonide has not been studied during lactation. Since only large-area application of potent corticosteroids is likely to have systemic effects on the mother, short-term topical application of corticosteroids is unlikely to pose a risk to the nursing infant through breast milk. However, it is a precaution to use the least potent medication on the smallest possible area of skin. It is especially important to ensure that the infant's skin does not come into direct contact with the treated area. Water-soluble creams or gels should only be applied to the breasts, as ointments may expose the infant to high concentrations of mineral oil through licking. Desonide cream or foam can be used on the nipples. If topical corticosteroids are applied to the breast or nipple area, they should be thoroughly wiped off before breastfeeding.
◉ Effects on Breastfed Infants
A mother applied a topical corticosteroid (isofluprednisolone acetate) with high mineralocorticoid activity to her nipples, resulting in QT interval prolongation, Cushing's syndrome-like symptoms, severe hypertension, growth retardation, and electrolyte imbalance in her 2-month-old breastfed infant. The mother had been using the cream due to nipple pain since the infant's birth.
◉ Effects on Lactation and Breast Milk
As of the revision date, no relevant published information was found.

Expert Opin Investig Drugs.2008 Jul;17(7):1097-104;J Drugs Dermatol.2010Apr;9(4):324-9.

Desonide is a triamcinolone acetone derivative, with the fluorine substituent at position 9 replaced by a hydrogen atom. It is a corticosteroid anti-inflammatory drug, applied topically as a cream, ointment, or lotion to treat various skin conditions. It has anti-inflammatory effects. It is an 11β-hydroxysteroid, 21-hydroxysteroid, 20-oxosteroid, corticosteroid, cyclic ketal, 3-oxo-Δ⁹Δ⁴-steroid, and primary α-hydroxyketone.
A non-fluorinated corticosteroid anti-inflammatory drug, used topically to treat skin diseases.
Desonide is a corticosteroid. The mechanism of action of desonide is as a corticosteroid hormone receptor agonist.
Desonide is a synthetic glucocorticoid used topically with anti-inflammatory activity. Desonide binds to glucocorticoid receptors in the cytoplasm, and the ligand-receptor complex is transported to the nucleus as a homodimer, where the glucocorticoid response element activates the transcription of glucocorticoid response genes. This drug induces the transcription of genes encoding anti-inflammatory proteins, including lipocortin-1, interleukin-10, interleukin-1 receptor antagonists, and neutral endopeptidase. Increased lipocortin-1 synthesis inhibits phospholipase A2, thereby inhibiting the release of arachidonic acid and controlling the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes.
A non-fluorinated corticosteroid anti-inflammatory drug used to treat skin diseases.
See also: desonide sodium phosphate (its active ingredient); glacial acetic acid; desonide (one of the components).
Indications
For the relief of inflammatory and pruritus symptoms in corticosteroid-responsive dermatitis.
Mechanism of Action
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic, and vasoconstrictive effects. The drug binds to cytoplasmic glucocorticoid receptors. This complex migrates to the cell nucleus and binds to genetic elements on DNA. This activates and inhibits various genes. However, it is believed that the mechanism of action of corticosteroids is through inducing the production of phospholipase A2-inhibiting proteins (collectively known as lipocortin). These proteins are presumed to control the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Desolide is a synthetic, non-fluorinated corticosteroid used for topical dermatological treatment. Corticosteroids are a class of steroids primarily composed of synthetic compounds, used topically as anti-inflammatory and antipruritic agents.

C24H32O6

416.51

416.219

638-94-8

5311066

White to off-white solid powder

1.3±0.1 g/cm3

580.1±50.0 °C at 760 mmHg

274 - 275ºC

196.9±23.6 °C

0.0±3.7 mmHg at 25°C

1.598

2.62

2

6

2

30

873

8

C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O

WBGKWQHBNHJJPZ-QHDHGWJCSA-N

InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15?,16?,17-,19+,20?,22-,23-,24+/m0/s1

(6aR,7S,8aS,8bS,11aR)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2,1:4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility in Formulation 1: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

Solubility in Formulation 4: 2% DMSO +49%PEG 300 +dd H2O: 10mg/mL

---

 (Please use freshly prepared in vivo formulations for optimal results.)